Abstract
Current tuberculosis (TB) treatment is based on a combination of drugs that were developed mostly in the central decades of the last century. Cure rates are high for drug sensitive strains of Mycobacterium tuberculosis (M. tb) when the recommended complex and lengthy treatment protocols are adhered to. However the difficulty in correctly prescribing and adhering to these protocols, the emergence of M. tb strains resistant to multiple drugs, and drug-drug interactions that interfere with optimal treatment of HIV and TB coinfected patients have generated a pressing need for improved TB therapies. Together with the ominous global burden of TB, these shortcomings of current treatment have contributed to a renewed interest in the development of improved drugs and protocols for the treatment of tuberculosis. This article highlights hurdles related to the optimized use of existing drugs and challenges related to the development of novel, improved products, focusing in particular on aspects inherent in TB drug clinical development. Concluding comments propose processes for more efficient development of new TB therapies.
Keywords: Tuberculosis (TB) drug development, pipeline, fluoroquinolones, nitroimidazoles, rifamycins, clinical trials
Infectious Disorders - Drug Targets
Title: Challenges Associated with Current and Future TB Treatment
Volume: 7 Issue: 2
Author(s): M. Laurenzi, A. Ginsberg and M. Spigelman
Affiliation:
Keywords: Tuberculosis (TB) drug development, pipeline, fluoroquinolones, nitroimidazoles, rifamycins, clinical trials
Abstract: Current tuberculosis (TB) treatment is based on a combination of drugs that were developed mostly in the central decades of the last century. Cure rates are high for drug sensitive strains of Mycobacterium tuberculosis (M. tb) when the recommended complex and lengthy treatment protocols are adhered to. However the difficulty in correctly prescribing and adhering to these protocols, the emergence of M. tb strains resistant to multiple drugs, and drug-drug interactions that interfere with optimal treatment of HIV and TB coinfected patients have generated a pressing need for improved TB therapies. Together with the ominous global burden of TB, these shortcomings of current treatment have contributed to a renewed interest in the development of improved drugs and protocols for the treatment of tuberculosis. This article highlights hurdles related to the optimized use of existing drugs and challenges related to the development of novel, improved products, focusing in particular on aspects inherent in TB drug clinical development. Concluding comments propose processes for more efficient development of new TB therapies.
Export Options
About this article
Cite this article as:
M. Laurenzi , A. Ginsberg and M. Spigelman , Challenges Associated with Current and Future TB Treatment, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001817
DOI https://dx.doi.org/10.2174/187152607781001817 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Mycobacterial Activity of Quinolones. Triazoloquinolones a New Class of Potent Anti-Mycobacterial Agents
Anti-Infective Agents in Medicinal Chemistry L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Analysis of DNA Microarray Data
Current Topics in Medicinal Chemistry Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Enzymatic Activity and Protein Interactions in Alpha/Beta Hydrolase Fold Proteins: Moonlighting Versus Promiscuity
Protein & Peptide Letters Prioritizing Disease Genes by Using Search Engine Algorithm
Current Bioinformatics Methicillin-Sensitive <i>Staphylococcus aureus</i> Pyogenic Iliopsoas Abscesses: A Case Series from Jodhpur, India
Infectious Disorders - Drug Targets Meet Our Editorial Board Member
Drug Delivery Letters Synthesis, Anticlotting and Antiplatelet Effects of 1,2,3-Triazoles Derivatives
Medicinal Chemistry Mycobacterial DNA GyrB Inhibitors: Ligand Based Pharmacophore Modelling and In Vitro Enzyme Inhibition Studies
Current Topics in Medicinal Chemistry Applications of Zirconium (IV) Compounds in Organic Synthesis
Current Organic Chemistry Toll-Like Receptors and Kidney Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Antibacterial, Antifungal and Anti-tubercular Activities of Chloroform Fraction of the Leaf Extract of Irvingia Gabonensis (African Bush Mango)
Anti-Infective Agents Molecular Insights into the Interaction of Ursolic Acid and Cucurbitacin from Colocynth with Therapeutic Targets of <i>Mycobacterium tuberculosis</i>
Letters in Drug Design & Discovery MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy Recent Advances in the Development of Small-Molecular Inhibitors Target HIV Integrase-LEDGF/p75 Interaction
Mini-Reviews in Medicinal Chemistry Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Cheminformatics in Anti-Infective Agents Discovery
Mini-Reviews in Medicinal Chemistry Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology